$MDGL

Kelley Shannon T sold $342K of MDGL

Kelley Shannon T (General Counsel) sold 664 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at $514.97 ($0.34M total) on 2026-08-17.

Original reporting
SEC EDGAR · Kelley Shannon T
Published Aug 20, 2026, 8:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 8:51 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MDGL
Bearish
medium confidence
Mentioned
$MDGL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDGLBearishLow
01

Why it matters

The sale reduces insider ownership modestly; market may view as neutral to slightly negative.

02

Market read

Small insider sale with limited price impact; traders may monitor for further insider activity.

03

What to watch

Potential upcoming clinical data or regulatory events not disclosed.

Relevance 4/10Novelty 4/10Timing: filed 2026-08-20

Background

Form 4 filing reports insider transactions for publicly traded companies.

Company-level read

Ticker impact

$MDGLBearishMedium confidence
Context

General Counsel Kelley Shannon T sold 664 shares for $341,940, reducing her stake to 11,474 shares.

Expected impact

Potential slight downward pressure in short term.

Evidence & confidence

Form 4 filing is primary source; sale size under $1M limits material impact.

Market effects

Minimal effect on biotech sector; typical insider sell.

No regional impact.

Low global relevance.

Counterpoint

Insider may be diversifying; sale does not reflect company fundamentals.

Key entities

  • Madrigal Pharmaceuticals, Inc.

    Biotech firm developing therapies for liver disease.

  • Kelley Shannon T

    General Counsel of Madrigal Pharmaceuticals.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDGLMed

MADRIGAL PHARMACEUTICALS, INC. (MDGL): Results of Operations and Financial Condition

MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates • Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% • As of June 30, 2026, more than 49,000 patient